The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
 
Miguel Angel Villalona-Calero
Stock and Other Ownership Interests - Moderna Therapeutics
Consulting or Advisory Role - Lilly
Speakers' Bureau - Amgen
Research Funding - Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Merck (Inst); Novocure (Inst); Tolero Pharmaceuticals (Inst)
 
Stephen J. Forman
Stock and Other Ownership Interests - Lixte Biotechnology; MustangBio
Consulting or Advisory Role - Alimera Sciences; Lixte Biotechnology; MustangBio; MustangBio
Research Funding - MustangBio
Patents, Royalties, Other Intellectual Property - MustangBio
 
Joycelynne Palmer
No Relationships to Disclose
 
Timothy W. Synold
Patents, Royalties, Other Intellectual Property - I received a patent covering methods of quantifying N.sup.2-(1-carboxyethyl)-2'-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG. The patent number is 11,179,361.
 
Lei Tian
No Relationships to Disclose
 
Ting Lu
No Relationships to Disclose
 
Colt A. Egelston
Consulting or Advisory Role - Novartis
 
Erminia Massarelli
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi Sankyo Co.; Genentech/Roche; Janssen Scientific Affairs; Lilly; Merck; Sanofi
Speakers' Bureau - AstraZeneca; Lilly; Merck; Mirati Therapeutics; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
 
Ravi Salgia
Consulting or Advisory Role - Abbvie; AstraZeneca; Iovance Biotherapeutics; Novartis
Speakers' Bureau - AstraZeneca; DAVA Oncology; Merck
 
Teresa Kim
No Relationships to Disclose
 
W Hans Meisen
Employment - Amgen
Patents, Royalties, Other Intellectual Property - Amgen
 
Jianying Zhang
Stock and Other Ownership Interests - CytoImmune Therapeutics (I)
Research Funding - CytoImmune Therapeutics (I)
Patents, Royalties, Other Intellectual Property - CytoImmune Therapeutics (I)
 
Thomas Waddington
No Relationships to Disclose
 
F. Edward Boas
Stock and Other Ownership Interests - ClariPACS; CloudMedx; Labdoor; Notable Labs; Qventus; Solugen; Xact Robotics
Research Funding - Boston Scientific; GE Healthcare; Guerbet
Patents, Royalties, Other Intellectual Property - US patent 8233586
 
Lihua Elizabeth Budde
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; BeiGene; Kite/Gilead; Loxo/Lilly; Novartis; nurix; Roche/Genentech
Research Funding - Amgen; AstraZeneca; Merck; MustangBio
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia.
Travel, Accommodations, Expenses - Kite/Gilead; Roche/Genentech
 
Omer Butt
Employment - Cytoimmune Therapeutics
Leadership - Cytoimmune Therapeutics
Stock and Other Ownership Interests - Cytoimmune Therapeutics
Travel, Accommodations, Expenses - Cytoimmune Therapeutics
 
Remus N. Vezan
Employment - Cytoimmune Therapeutics
Leadership - Cytoimmune Therapeutics
Stock and Other Ownership Interests - Abbvie; CytoImmune Therapeutics; Gilead Sciences; Merck
Travel, Accommodations, Expenses - CytoImmune Therapeutics (I)
 
Michael A. Caligiuri
Stock and Other Ownership Interests - BeiGene; CytoImmune Therapeutics; Precision Technologies
Consulting or Advisory Role - Breakthrough Exchange; Cellular Biomedicine Group; Cytovia Therapeutics; OncoC4
Patents, Royalties, Other Intellectual Property - I hold numerous patents and have numerous patents pending regarding cancer immune therapy.
Other Relationship - CytoImmune Therapeutics; Precision Technologies
 
Jianhua Yu
Stock and Other Ownership Interests - CytoImmune Therapeutics
Research Funding - CytoImmune Therapeutics
Patents, Royalties, Other Intellectual Property - CytoImmune Therapeutics